Mural Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mural Oncology generated cash of -$194,249,000, which is less than the previous year. Cash used in financing activities reached the amount of $468,811,000 last year. Net change in cash is therefore $271,110,000.
Cash Flow
| 2021 | -156.66M | -4.38M | 161.05M |
|---|---|---|---|
| 2022 | -168.58M | -5.51M | 174.09M |
| 2023 | -194.24M | -3.45M | 468.81M |
MURA Cash Flow Statement (2021 – 2023)
| 2023 | 2022 | 2021 | |
|---|---|---|---|
Cash at beginning of period | 0 | 0 | 0 |
Operating activities | |||
Net income | -207.44M | -189.80M | -175.43M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||
Depreciation and amortization | 2.56M | 1.54M | 1.47M |
Stock-based compensation expense | 24.10M | 11.93M | 11.50M |
| Deferred income tax benefit | 24.10M | 11.93M | 11.50M |
| Changes in operating assets and liabilities: | |||
Accounts receivable, net | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 |
Accounts payable | 0 | 0 | 0 |
Cash generated by operating activities | -194.24M | -168.58M | -156.66M |
Investing activities | |||
Purchases Of Investments | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.45M | -5.51M | -4.38M |
Acquisitions Net | 0 | 0 | 0 |
Cash generated by investing activities | -3.45M | -5.51M | -4.38M |
Financing activities | |||
Common Stock Issued | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 |
Cash used in financing activities | 468.81M | 174.09M | 161.05M |
Net Change In Cash | 271.11M | 0 | 0 |
Cash at end of period | 271.11M | 0 | 0 |
| Data source |